Rapid viral expansion and short drug half-life explain the incomplete effectiveness of current herpes simplex virus 2-directed antiviral agents.
about
Understanding natural herpes simplex virus immunity to inform next-generation vaccine designMathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes.Mathematical Modeling Predicts that Increased HSV-2 Shedding in HIV-1 Infected Persons Is Due to Poor Immunologic Control in Ganglia and Genital MucosaHerpes simplex virus-2 transmission probability estimates based on quantity of viral sheddingHerpes simplex virus-2 genital tract shedding is not predictable over months or years in infected persons.Rapid and Profound Shifts in the Vaginal Microbiota Following Antibiotic Treatment for Bacterial Vaginosis.Pharmacokinetic and pharmacodynamic considerations of antimicrobial drug therapy in cancer patients with kidney dysfunctionChanges in the contribution of genital tract infections to HIV acquisition among Kenyan high-risk women from 1993 to 2012.Efficacy of N-methanocarbathymidine against genital herpes simplex virus type 2 shedding and infection in guinea pigs.Image analysis for accurately counting CD4+ and CD8+ T cells in human tissue.Herpes simplex virus type 2-infected dendritic cells produce TNF-α, which enhances CCR5 expression and stimulates HIV production from adjacent infected cells.The interaction of HSV-1 tegument proteins pUL36 and pUL37: a novel target for antivirals that inhibit viral assemblyA Fixed Spatial Structure of CD8 T Cells in Tissue during Chronic HSV-2 Infection
P2860
Q26741484-1EB603EC-9C5A-4475-9BA4-B55D103C1B60Q27324453-3F08474C-88AC-432E-8D87-7A3CD234FFBAQ27347896-A8101BA4-19DF-43CD-8FF7-89554CF218FDQ28236882-70B19B2F-ACBC-4493-A191-092FF2540A69Q34464387-6C7AA84E-F040-47F3-A342-02F146ECBCD6Q35560100-EA131BD0-77FB-4F16-905A-3B3466ADD7CEQ35819409-9EABF0C1-04F9-4035-81FC-7DA0B5568A30Q36076166-BA8E319E-0CF8-46BD-B3E9-EAF949DACF01Q41120363-13220DB8-EFD4-4E94-BC82-8AB661F4B5FCQ41161711-EC49386E-8621-4322-B922-43F2747EDEFDQ41357293-C274F069-96A6-4FCB-B301-DABC56873682Q57076505-7BEC1AD3-4F77-4EB4-818B-82E5828A39FFQ57269664-8FCDEDD1-AF53-474A-8F68-DB0875AEAD56
P2860
Rapid viral expansion and short drug half-life explain the incomplete effectiveness of current herpes simplex virus 2-directed antiviral agents.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Rapid viral expansion and shor ...... s 2-directed antiviral agents.
@en
Rapid viral expansion and shor ...... s 2-directed antiviral agents.
@nl
type
label
Rapid viral expansion and shor ...... s 2-directed antiviral agents.
@en
Rapid viral expansion and shor ...... s 2-directed antiviral agents.
@nl
prefLabel
Rapid viral expansion and shor ...... s 2-directed antiviral agents.
@en
Rapid viral expansion and shor ...... s 2-directed antiviral agents.
@nl
P2860
P356
P1476
Rapid viral expansion and shor ...... s 2-directed antiviral agents.
@en
P2093
David A Swan
Joshua T Schiffer
P2860
P304
P356
10.1128/AAC.01114-13
P407
P577
2013-09-09T00:00:00Z